← Back to Search

Arm A: Provider Educational Intervention for Alzheimer's Disease (ORCHID Trial)

N/A

Waitlist Available

Led By Magdalena I Tolea, PhD

Research Sponsored by Florida Atlantic University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline, 3 months, 6 months, and 12 months post-intervention

Awards & highlights

ORCHID Trial Summary

This trial tests a protocol to help rural communities diagnose and treat Alzheimer's and dementia better.

Eligible Conditions

Alzheimer's Disease

ORCHID Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline, 3 months, 6 months, and 12 months post-intervention

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline, 3 months, 6 months, and 12 months post-intervention

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 3 months, 6 months, and 12 months post-intervention for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in AD knowledge

Change in AD literacy treatment plan.

Change in rates of new dementia diagnosis and treatment

+1 more

Secondary outcome measures

Change in caregiver burden

Change in caregiver self-efficacy

Change in provider confidence in establishing an ADRD diagnosis and treatment plan

+2 more

ORCHID Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Arm A: Provider Educational InterventionExperimental Treatment1 Intervention

Providers receiving education/support from neurology teams, Adult Gerontological Nurse Practitioner (AGNP) assessments/recommendations, and training of office staff regarding ADRD and community resources support for patients/caregivers.

Group II: Arm B: Provider ControlActive Control1 Intervention

Providers receiving AGNP assessments/recommendations only.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Florida Atlantic UniversityLead Sponsor

29 Previous Clinical Trials

9,393 Total Patients Enrolled

University of MiamiOTHER

899 Previous Clinical Trials

409,396 Total Patients Enrolled

Palm Beach State CollegeUNKNOWN

Media Library

Arm A: Provider Educational Intervention Clinical Trial Eligibility Overview. Trial Name: NCT05760521 — N/A

Alzheimer's Disease Research Study Groups: Arm A: Provider Educational Intervention, Arm B: Provider Control

Alzheimer's Disease Clinical Trial 2023: Arm A: Provider Educational Intervention Highlights & Side Effects. Trial Name: NCT05760521 — N/A

Arm A: Provider Educational Intervention 2023 Treatment Timeline for Medical Study. Trial Name: NCT05760521 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Could you tell me the total number of individuals taking part in this experiment?

"Affirmative. Clinicaltrials.gov details that this clinical trial is currently seeking participants, having first been posted on April 1st 2022 and recently modified on February 27th 2023. 460 individuals need to be enlisted from 2 distinct medical centres."

Answered by AI

Are there any available opportunities for individuals to enroll in this medical trial?

"Indeed, the information available on clinicaltrials.gov indicates that enrollment for this medical trial is still ongoing after its initial posting in April of 2022. Currently, 460 participants are sought from two distinct sites."

Answered by AI

What is the ultimate aim of this research endeavor?

"The primary indicator of this trial's success, which will be monitored at baseline and during 3-monthly intervals up until the 12-month mark, is a variation in referrals to Area Support Services. Secondary outcome metrics include an alteration in provider understanding related to Alzheimer's disease (measured by the Alzheimer’s Disease Knowledge Scale), shifts in clinician confidence concerning ADRD diagnosis and treatment planning (assessed with the General Practitioners' Attitude & Confidence Scale for Dementia), as well as transformations in caregiver burden ascertained through the Zarit Burden Inventory."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Optimizing Rural Community Health Through Dementia Detection and Care

Lisa A Wiese 2022. "Optimizing Rural Community Health Through Dementia Detection and Care". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05760521.